Congenital muscular dystrophy: merosin deficient form …

Neuromuscular Disorders

Updated 12.25.2023
Released 01.17.2001
Expires For CME 12.25.2026

Congenital muscular dystrophy: merosin deficient form

Authors: Neil Datta MD, Partha Ghosh MD

See Contributor Disclosures

Editor: Aravindhan Veerapandiyan MD

Congenital muscular dystrophy: merosin deficient form

In This Article

Quick Link

Introduction

Overview

Congenital muscular dystrophies occur with a frequency of 1 in 20,000 births, with a prevalence of 1 in 100,000. They manifest as hypotonia and muscle atrophy at birth, but there is significant clinical and genetic variation. Merosin (laminin alpha-2, also known as LAMA2) is a component of the basal lamina in muscle that is tightly bound to the dystrophin-associated membrane complex and is responsible for about half of the “classical” cases of congenital muscular dystrophy. Brain MRIs of these patients show diffuse white matter signal abnormality, but it does not affect cognition. In this article, the authors describe the clinical and molecular aspects of this disease. Implementation of new care standards, aids in diagnosis, and gene-based therapies that could likely improve the outcome of this disease will also be discussed. The merosin-deficient form of congenital muscular dystrophy will be referred to as LAMA2-related congenital muscular dystrophy (LAMA2-CMD) in this article.

Key points

	• LAMA2 (merosin) is a component of the basal lamina of skeletal muscles and is associated with the most frequent form of congenital muscular dystrophy.
	• Elevated creatine kinase level and white matter signal abnormality on brain MRI are the hallmarks of this disorder.
	• The availability of genetic testing has simplified and expedited the diagnosis of this disorder.
	• Supportive treatment provides long-term clinical benefit.
	• Gene-based research into putative treatments is ongoing.

Historical note and terminology

Congenital muscular dystrophy was first described in detail by FE Batten in 1903, including three cases with clinical features of muscular dystrophy, which was termed "infantile myopathy" (08). Congenital muscular dystrophy was then referred to as amyotonia congenita to distinguish this group of atrophic muscle diseases from "myotonia congenita" or Thomsen disease. Further histological observations led to the term "congenital muscular dystrophy" in the late 1960s. Since then, various forms have been recognized with or without brain involvement, demonstrating the clinical heterogeneity of congenital muscular dystrophy (06). Congenital muscular dystrophy was traditionally classified as a subgroup of congenital myopathies with an onset in the first 6 months of life by the Research Group on Neuromuscular Diseases of the World Federation of Neurology (63), but with continued advances in our knowledge of the disease, it was found to present within the first 2 years of life (44). Additionally, congenital muscular dystrophies with cerebral involvement (Fukuyama disease, Walker-Warburg syndrome, and muscle-eye-brain disease) were separated into a distinct category of congenital muscular dystrophy associated with glycosylation defects (33). The most prevalent type of congenital muscular dystrophy without clinical involvement of the central nervous system was called "classical" or "occidental" congenital muscular dystrophy (98). Gene discoveries for dystrophin and related membrane or basal lamina proteins revealed the genetic basis of the various forms of congenital muscular dystrophies, including the merosin (LAMA2)-deficient form (96). In light of these genetic findings, muscular dystrophies, including congenital muscular dystrophies, are now best classified according to the genetic and protein defects they harbor (64). Close to half of these cases are related to primary or secondary LAMA2 deficiency (MDC1 A-D) best identified by laminin-alpha 2 staining of muscle biopsies (42). Primary LAMA2-CMD (MDC1A) is an autosomal recessive form of muscular dystrophy due to mutations in the laminin alpha-2 (LAMA2) gene and shows a clinical onset within the first 6 months of life. Congenital inflammatory myopathy, described in the past, has a similar clinical presentation and histological features; therefore, it is a fair assumption that most cases of “congenital inflammatory myopathy” actually represented cases of LAMA2-CMD (76). Late-onset, limb-girdle type of muscular dystrophy has also been reported in patients with partial LAMA2 deficiency with missense mutations in the LAMA2 gene (03; 95). Secondary LAMA2 deficient congenital muscular dystrophy can be associated with glycosylation-related gene defects of fukutin (Fukuyama muscular dystrophy), fukutin-related protein (FKRP) gene (MDC1C), and LARGE gene (MDC1D).

Clinical manifestations

Presentation and course

LAMA2 is expressed in many tissue types, including skeletal muscle, cardiac muscle, Schwann cells, and trophoblasts. Patients with LAMA2-CMD experience multisystem involvement. Infants with LAMA2-CMD present with hypotonia and are “floppy” at birth. Early symptoms often include axial weakness and upper, more than lower, limb weakness. Uncommonly, arthrogryposis can be present; rarely, severe respiratory insufficiency may also be present. The infants often have poor suck and cry, multiple joint contractures, and motor development delay (the most common finding). Despite the delay in motor skills, no facial or extraocular muscle weakness or sensory loss is usually noted. Deep tendon reflexes are often decreased. LAMA2-CMD has associated elevated CK levels (up to five times upper limit of normal, often > 1,000 IU/L). Most of these patients do not achieve independent ambulation (29; 107; 47). In addition, evidence of a demyelinating sensorimotor neuropathy may be present within the first 6 months of life; however, neuropathy is not considered a hallmark feature of this disease (80). Bone density can also be affected (09).

The extent of laminin-alpha2 deficiency dictates disease severity in most cases. In the least severe cases, proximal muscle weakness and poor feeding may be the major concern in the first few months of life (97; 43). Partial loss of laminin-alpha 2 manifests as a late-onset, limb girdle-type muscular dystrophy form of LAMA2-CMD. This can present with similar symptoms as early onset LAMA2-CMD but considerably milder with wider phenotypic variability, and most patients can develop the ability to walk. Complete laminin-alpha2 loss, on the other hand, results in an early-onset congenital form of LAMA2-CMD characterized by severe hypotonia, muscle weakness, skeletal deformity, nonambulatory status, and respiratory insufficiency (68).

Frequently, children have normal intelligence combined with an MRI of the brain exhibiting a diffuse white matter abnormality resembling leukodystrophy. Rarely, patients have intellectual disability with severe brain malformations (56; 57; 91; 78). Partial merosin deficiency due to LAMA2 mutations is also associated with T2 signal abnormalities of the cerebral white matter (10; 75).

Seizures can occur in early-onset LAMA2-CMD and are likely related to neuronal migration abnormalities (103; 29; 67). Work looking at the epileptic phenotype in detail has found it to represent up to one third of individuals with early-onset LAMA2-CMD (107; 66). Natera-de Benito and colleagues provided a detailed investigation of epilepsy in this population, which though a major phenotype with significant impact on the quality of life for both the patient and family, had not been previously characterized in a systematic, well-described cohort of patients (66). They found that the epilepsy: (a) is typically drug-resistant and presents with middle childhood-onset focal seizures that have prominent visual and autonomic features; (b) has a consistent correlation with neuroimaging, suggesting that the extension of the polymicrogyria may serve as a predictor of epilepsy occurrence; (c) was significantly more prevalent in those individuals who had more extensive cortical malformations; and (d) had no association with the patients' motor ability, the size of their white matter abnormalities, or the amount of residual merosin expressed on muscle.

Cardiac abnormalities are predominantly reported in patients with complete LAMA2 deficiency. Initially, only two cases could be found in the literature with cardiac involvement that had partial LAMA2 deficiency (11; 52); however, newer case reports highlight cardiac involvement in partial laminin-alpha 2 chain deficiency also (68). Asymptomatic dilated cardiomyopathy with decreased ejection fraction has been reported in some patients (90; 67). Routine cardiac assessment monitoring in this population is, therefore, important due to the potential for severe presentation, even in those individuals with residual expression of LAMA2.

As the disease progresses, affected individuals can develop facial muscle weakness and macroglossia, which results in typical myopathic facies with a protruded tongue. Weakness of intercostal and accessory muscles results in progressive restriction of the chest wall, decreased lung volume, reduced alveolar gas exchange, and eventually restrictive respiratory insufficiency. Affected individuals also experience skeletal changes such as proximal joint contractures and scoliosis. Scoliosis may result in lumbar and thoracic lordosis, which can interfere with breathing. The most common cause of death in early-onset LAMA2 muscular dystrophy is caused by respiratory tract infection, and 30% of them die within the first decade of life (68).

Prognosis and complications

Most motor dysfunction is noted within the first few weeks, with an initial sharp decline followed by some improvement and the ability to eventually attain some axial functionality. That being said, patients typically do not achieve ambulatory function (29; 84). Morbidity and mortality are usually due to secondary complications of underlying weakness. Most commonly, morbidity and mortality are directly related to respiratory or pulmonary insufficiency secondary to accessory and intercostal muscle weakness, especially in more severe LAMA2-CMD cases. Thus, a notable portion of patients, as high as a third of patients, may need noninvasive ventilatory support (29; 84). Complicating this is swallowing and feeding difficulty, resulting in aspiration, and subsequent complicating pneumonia. Premature death may occur from pneumonia or other respiratory complications. In a series by Pegoraro and colleagues, 4 of 22 patients died between 5 and 10 years of age (77). Thus, most patients in the London-based Dubowitz Neuromuscular Center study were noted to have gastrostomy tube needs (84). Awareness of the risk of cardiac and CNS complications (including seizures) and early detection can significantly reduce morbidity. A patient with merosin-deficient congenital muscular dystrophy was reported to have malignant hyperthermia in the absence of classic triggering agents (89). The life expectancy in congenital muscular dystrophy is not known but is changing with improved care standards.

Clinical vignette

A female infant was a product of a nonconsanguineous union born after a normal pregnancy. There was no family history of neuromuscular disease. Poor feeding and failure to thrive were noted at 2 months of age. Examination revealed generalized hypotonia and muscle wasting with hyporeflexia. Baby was otherwise alert and attentive, and no cranial nerve abnormalities were noted. A nerve conduction study at 5 months of age revealed moderately slow motor and sensory nerve conduction responses without conduction block. Needle EMG examination showed grade II fibrillations and polyphasic motor unit potentials. Serum creatine kinase levels were 3275 IU. A muscle biopsy at the time showed muscle fiber necrosis, an increase of connective tissue, and marked lymphocytic inflammation.

Congenital muscular dystrophy: merosin deficient form (muscle histology showing muscle fiber necrosis)

Paraffin sections from muscle biopsy were stained with hematoxylin-eosin (A) and modified Gomori trichrome (B). There is variation of muscle fiber size, increased connective tissue, and some infiltration of inflammatory cells (mag...

Based on the muscle histology, a diagnosis of infantile inflammatory myopathy was made, and the child was started on daily prednisone treatment. She was able to sit at 12 months of age but remained nonambulatory. Her cognitive skills and speech were appropriate for her age. Repeat muscle biopsy at 2 years of age that was immunostained for laminin, dystrophin, and sarcoglycans showed an absence of merosin (LAMA2).

Congenital muscular dystrophy: merosin deficient form (muscle histology showing absence of laminin alpha2)

Merosin immunolabeling in normal (A) and merosin-deficient (B) muscles were done with monoclonal antibody to the C-terminal portion of merosin, which was coupled to Texas red. Note the complete absence of bright signal from the su...

A brain MRI showed abnormal white matter with some posterior dominance and no cortical defect. During a 3-year follow-up, there was no clinical deterioration in her condition, and she did not develop any central nervous system symptoms. Steroid treatment was discontinued. The mother of the child had a subsequent pregnancy where merosin staining from a chorion villus sample revealed that the fetus was not affected. This finding was confirmed by genetic linkage analysis.

Cytomegalovirus (brain MRI)

T2-weighted MRI images show a marked high intense T2 signal in the white matter. (Contributed by Dr. Gyula Acsadi.)

Biological basis

Etiology and pathogenesis

More than 10 genes are associated with different congenital muscular dystrophies, elucidating pathologic mechanisms related to processing of proteins (42). Merosin-deficient congenital muscular dystrophy is an autosomal recessive condition due to mutations in the LAMA2 gene on chromosome 6q22-23 (41; 40; 71). The LAMA2 gene is more than 260 kb long and contains 65 exons, with a transcript that is almost 10 kb in size (116). The LAMA2 encodes the laminin-alpha 2 chain, one of the subunits of laminin-211.

The laminins are members of the large basal lamina glycoprotein complex, and they consist of one heavy (alpha) and two light beta and gamma chains. In muscle, the heavy chain is the laminin alpha2-chain (lamininM), or merosin.

Dystrophin and associated complex (schematic design)

Laminin-alpha2 (merosin) is an extracellular component and linked to dystroglycan (from Kanagawa M, Toda T. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 2006;...

Merosin consists of 3110 amino acids and has three globular (VI; IVb; and IVa) and three rod (V; IIIa; and IIIb) domains. Domains I and II participate in the laminin triple-coiled structure. The G domain is the C-terminal part of merosin, which binds either the cell membrane dystroglycan or the integrin (alpha7 beta1) complex (77; 59). In electron microscopic studies of normal muscle, merosin in basal lamina is distributed in zones and localized to the lamina lucida of basal lamina. Merosin molecules form short, fine, cross-bridge fibrils connecting the basal lamina to the muscle plasma membrane (88). The association of laminin with dystroglycan suggests that it may have a role in maintaining the integrity of muscle cell membrane during contraction and stretching (55). Furthermore, laminins are known to affect cell adhesion, cell migration, and muscle regeneration (115; 99; 48). Massive muscle fiber degeneration occurs in the early stage of LAMA2-CMD and may contribute to the severe dystrophic changes in muscle seen in early infancy (38). The loss of muscle‐matrix interaction plays a central role in the pathogenesis of LAMA2-CMD: mouse model intramuscular administration of laminin 111 reduces apoptosis, increases fiber size, and improves muscle strength by stabilizing the interaction between the muscle membrane and extracellular matrix in Lama 2–deficient mice (83; 19). Apoptotic cell death has been implicated in muscle fiber necrosis, and antiapoptotic agents show some benefit in mouse models of disease (23; 30). The amount of residual laminin alpha 2 correlates with the phenotype severity in transgenic mice.

Laminins are present in most tissues, and merosin is found in skeletal muscle and also in skin, heart, peripheral nerve, brain, and placenta. In the peripheral nervous system, merosin is localized to the endoneural basal membrane, where it is likely to bind the dystroglycan complex and alpha6 beta4 integrin on the surface of Schwann cells (110). Interestingly, expression of an agrin minigene (agrin binds to basement membrane and to alpha-dystroglycan) restored muscle function in a transgenic mouse model (dy mouse) for congenital muscular dystrophy (61). An AAV9 vector containing miniagrin (AAV9-Mini-Agrin) has been found to be beneficial in extending lifespan and improving muscle pathology in the dy mouse (81). It is well established that laminins play a role in peripheral nerve myelin formation, and a myelin abnormality is likely to be responsible for the slow nerve conduction velocity in patients with congenital muscular dystrophy. In laminin alpha-2 null mutant mouse (dy3K/dy3K), nerve myelination occurred, but Schwann cells lacked basal lamina in the spinal roots, suggesting that basal lamina is not an absolute requirement for myelination in vivo. In this mouse model, the motor conduction velocity of the sciatic nerve was significantly reduced, probably due to small axon diameter, thin myelin sheath, and patchy disruption of the basal lamina at the nodes of Ranvier (65). A single case report showed a severe loss of myelin in peripheral nerves, which was associated with a single base pair mutation that affected the laminin-laminin binding (74). However, no myelin sheath defect was found in a few nerve biopsies from other patients (94).

The mutations seen in LAMA2 gene are mainly single base pair changes or small deletions, causing loss of function in 95% of cases (34). These mutations are scattered throughout the gene, but about one third are localized in the C-terminal domain (77; 16; 71). In a cohort of 26 patients from Portugal, one third had exon 56 deletion (72). Total absence or partial loss of merosin has been found in cases of congenital muscular dystrophy with similar clinical severity. Single-point missense mutations can produce partial merosin deficiency and a milder late-onset muscular dystrophy (03; 71). A case report indicated that even a loss-of-function mutation in the LAMA2 gene caused only a mild form of disease, suggesting the existence of potential disease modifiers (79). In other cases, partial merosin deficiency is unrelated to LAMA2 gene mutations and may be a secondary effect of abnormalities in other basal lamina components such as fukutin (37). In general, nonsense mutations in LAMA2 cause more severe phenotype than missense or splice site mutations (29).

LAMA2 gene mutations associated with dystrophic muscle pathology, like congenital muscular dystrophy, have been found in mice (dy and dy2J) (108). The dy mouse lacks merosin completely, develops progressive weakness by 4 weeks of age, and dies within 2 to 3 months. The dy2J mutant mouse has a truncated merosin protein corresponding to a less severe clinical course.

The relationship between brain abnormalities and merosin deficiency is not well understood. Diffusion-weighted images from the brain suggest that there is an increase in water content in the cerebral white matter (01), a theory also supported by MR spectroscopy (50). Extensive white matter abnormality exists in almost all complete or partial merosin-deficient patients; cortical migrational abnormalities, polymicrogyria, cortical heterotopia, or cerebellar hypoplasia can be found in some patients (91; 78). The white matter abnormalities seen on MRI resemble the demyelinization characteristic of some leukodystrophies, but histological studies failed to document myelin abnormalities (94). Studies have demonstrated that LAMA2 stimulates oligodendrocytes to extend elaborate membrane sheets using an integrin-linked kinase (13). Merosin has been localized to the basement membrane of capillaries in the mature brain, which suggests that disruption of the blood-brain barrier and serum extravasation are responsible for the abnormal white matter signal on MRI (104). The dy mouse also shows loss of merosin from the brain capillaries; however, MRI of the brain does not reveal any white matter abnormalities (20). Dysfunction in agrin, a basal lamina glycoprotein crucial for the formation and maintenance of neuromuscular junctions, potentially contributes to the impaired neuromuscular transmission described in LAMA2-CMD (47). A review further details the correlation between brain dysfunction in LAMA2-CMD from human case reports and mouse models (05).

Differential diagnosis

Confusing conditions

Congenital muscular dystrophy can be distinguished from the congenital myopathies (eg, structural defects of muscle or metabolic myopathies) based on large elevations of creatine kinase levels and muscle histology. Congenital muscular dystrophy should be a consideration in the phenotype of a “floppy infant.” Lack of encephalopathy, normal cranial nerve findings, decreased or absent deep tendon reflexes, and decreased muscle bulk are important clues for differentiating congenital muscular dystrophy from central hypotonia. Spinal muscular atrophy (type I) and congenital myasthenia can manifest within the first month of life, whereas LAMA2 congenital muscular dystrophy is less severe and is usually recognized later. The presence of high creatine kinase levels is diagnostic of a congenital muscular dystrophy. Nerve conduction studies and EMG can help differentiate a congenital muscular dystrophy from spinal muscular atrophy and myasthenia. Rigid spine syndrome is a rare congenital muscular dystrophy characterized by early rigidity of the spine and respiratory insufficiency and has been associated with mutations of a selenoprotein (SEPN1) gene on chromosome 1p35-36 (60).

Congenital muscular dystrophies are a heterogeneous group of early-onset muscular dystrophies with or without clinical signs of central nervous system involvement. The presence of structural abnormalities in the central nervous system suggests a deficiency in one of the glycosyltransferases that may cause Fukuyama muscular dystrophy, Walker-Warburg disease, or "muscle-eye-brain disease” (MEB) (33). The distinguishing features between these subgroups are severe brain involvement and dysmorphic features. Interestingly, a secondary decrease of LAMA2 occurs in Fukuyama muscular dystrophy but not in Walker-Warburg syndrome (105; 112). About one half of occidental congenital muscular dystrophies are caused by LAMA2 deficiency, whereas the rest are related to defects in integrins, alpha-actinin, or have unknown etiology (69; 21). Inherited congenital muscular dystrophy with no LAMA2 abnormality was linked to chromosome 4p in some families (85). It must be noted that partial LAMA2 deficiency can be responsible for early-onset congenital muscular dystrophy, as well as late-onset muscular dystrophy (most likely limb-girdle type) (03; 93). In these cases, a white matter abnormality is also present on MRI. Late-onset muscular dystrophy with partial LAMA2 deficiency can occur in adults, but some of these cases are secondary and not linked to the LAMA2 gene (10; 39). Ambulatory ability was associated with a missense, single-point mutation or premature termination in an exon with potential for alternative splicing, all resulting in a partial deficiency (71).

Diagnostic workup

If congenital muscular dystrophy is suspected in an infant, serum creatine kinase levels will confirm primary muscle involvement, demonstrating CPK up to five times the upper limit of normal, commonly more than 1000 IU/L (87; 47). Patients with congenital myopathies due to structural defects in the muscle fibers usually do not have high creatine kinase. Nerve conduction studies and needle EMG are useful to differentiate congenital muscular dystrophy from motor neuron disease or myasthenia. Nerve conduction study shows mild to moderate delay in motor nerve conduction (102). Brain MRI is highly useful to exclude severe brain malformation, especially if the patient has dysmorphic features. A diffuse white matter abnormality is almost always diagnostic of a LAMA2-CMD when combined with a high CK level. Occasionally, more severe brain abnormalities have also been found (91; 78). Lower limb MRI has also been used more frequently, demonstrating fatty replacement patterns, but may mimic other muscular dystrophies (67; 36; 92). Muscle biopsy frequency has declined with the advent of genetic sequencing. Specific immunostaining for dystrophin and associated protein complex, including LAMA2, can assist in the diagnosis. Antibodies to both the C-terminus and the central domains of LAMA2 are required to recognize partial merosin deficiencies. If a muscle biopsy is unavailable, LAMA2 staining of a skin biopsy can be informative (86).

Genetic testing for LAMA2 gene mutations has become available. O'Grady and colleagues evaluated 85 congenital muscular dystrophy cases over the last 20 years using conventional approaches of biopsy and immunohistochemistry compared to next-generation sequencing and found that with conventional testing, 51 (60%) remained undiagnosed (70). Twenty-eight of the 51 consented to next-generation sequencing, resulting in 11 confirmed diagnoses. Using a combination of approaches, 51% of patients received a genetic diagnosis. As the cost of genetic testing continues to decrease and its availability increases, earlier and more reliable diagnosis is possible (71).

Management

No effective therapy is available for LAMA2-CMD. There is a “consensus statement” published on care standards that is applicable for this form of congenital muscular dystrophy (106; 44). Supportive treatment includes gastric tube placement for feeding, scoliosis surgery, and treatment of respiratory illnesses. Physical therapy may help prevent muscle contractures. Health-related quality of life and the factors that impact it are key components of therapy (15). In the future, urine miRNA analysis may help in the staging of disease (62). Multiple future therapies are being investigated.

No clinical trials with steroids have been reported for LAMA2-CMD. Therapeutic approaches tried in the animal models of the disease have shown mixed results. In a rodent model of LAMA2-CMD, the inhibition of apoptosis by overexpression of Bcl2 improved the clinical outcome (31; 18). Ablation of myostatin (a muscle growth inhibitory factor) did not provide benefit in a mouse model (51). Various compounds are under investigation that can induce a “read-through” of stop codons in the laminin-alpha2 gene (02; 58). Exon-skipping technology with novel oligomers can partially rescue laminin2 expression (35). Other preclinical studies using proteosome inhibitors, agrin molecule and a laminin-alpha 1 residue are under investigation in animal models (26; 12; 54). Various treatment trials with losartan (an angiotensin-2 type 1 receptor blocker), alpha-7 integrin overexpression, and laminin-111 (an embryonic form of laminin) showed clinical efficacy in LAMA2 deficient mice and hold promise in future treatments for congenital muscular dystrophy (17; 22; 04; 101). Metformin was shown to increase weight gain, energy efficiency, muscle function, and histology in female mouse models (to some extent in males) of LAMA2-CMD (25).

Preclinical treatment approaches. Approaches successfully used in other neuromuscular disorders are also being investigated for LAMA2-CMD. Different approaches for developing a therapy for LAMA2-CMD have been devised and primarily fall into three categories. The first aims to stabilize or restore the structure and function of the basement membrane as well as its interactions with adjacent cells. The second aims to modulate cellular events caused by LAMA2 loss. The third group targets the genetic defect in LAMA2-CMD, either through mRNA processing and translational read-through, using oligonucleotides or small molecules, respectively, or correcting the causative mutation using CRISPR/Cas9 system.

In the first group, intramuscular administration of laminin 111 resulted in membrane stabilization and functional muscle improvement in Lama 2–deficient mouse models (83). Laminin-111 protein was upregulated in muscles and nerves of Lama2^dy2J/dy2Jmice (45). Specifically, it rescued myelination and nerve conduction velocities in peripheral nerves.

In the second group, mini-agrin was shown to ameliorate LAMA2-deficient phenotype in animal models (82). An AAV9-Mini-Agrin vector was tested in a mouse model of the disease and improved muscle pathology and lifespan (81). AAV insertion of shortened associated αLN linker protein DNA demonstrated increased strength and sciatic myelination (53). Omigapil, an apoptosis inhibitor (related to GAPDH and SIAH1 enzymes), has also shown a reduction in muscle tissue loss in LAMA2-CMD (113); clinical trials are ongoing in early phases.

In the third group, AAV-based gene replacement therapy has been difficult due to the large gene size. However, Packer and colleagues created an AAV-deliverable “microlaminin” gene based on precedence from micro-dystrophin (73). It demonstrated successful microlaminin expression as well as improved muscle strength but did not address all disease phenotypes. Antisense oligonucleotide-based exon skipping has been another technique used in muscular dystrophies; removal of a stop codon promotes merosin re-expression and resulted in mild improvement in a mouse model of LAMA2-CMD (04). Kemaladewi and colleagues delivered CRISPR-Cas9 genomic editing components using AAV and demonstrated the ability to correct a splice site mutation in exon 2 and restore truncated merosin to full length in a mouse model (46). Another example using CRISPR/Cas9d activation system confirmed earlier work (28) and targeted the Lama1 gene promoter delivered by adeno-associated virus (AAV9) (45).

Detailed information on both the underlying pathomechanisms and strategies for therapy development that address each of these areas and animal models for testing has been published in a series of review articles (109; 68; 114; 07; 27; 49; 80; 111).

Media

References

01: Alkan A, Sigirci A, Kutlu R, Aslan M, Doganay S, Yakinci C. Merosin-negative congenital muscular dystrophy: diffusion-weighted imaging findings of brain. J Child Neurol 2007;22(5):655-9. PMID 17690079
02: Allamand V, Bidou L, Arakawa M, et al. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. J Gene Med 2008;10(2):217-24. PMID 18074402
03: Allamand V, Sunada Y, Salih MA, et al. Mild congenital muscular dystrophy in two patients with an internally deleted laminin alpha2-chain. Hum Mol Gen 1997;6:747-52. PMID 9158149
04: Aoki Y, Nagata T, Yokota T, et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 2013;22(24):4914-28. PMID 23882132
05: Arreguin AJ, Colognato H. Brain dysfunction in LAMA2-related congenital muscular dystrophy: lessons from human case reports and mouse models. Front Mol Neurosci 2020;13:118. PMID 32792907
06: Banker BQ. The congenital muscular dystrophies. In: Engel AG, Franzini-Amstrong C, editors. Myology. New York: McGraw-Hill, 1994.
07: Barraza-Flores P, Bates CR, Oliveira-Santos A, Burkin DJ. Laminin and integrin in LAMA2-related congenital muscular dystrophy: from disease to therapeutics. Front Mol Neurosci 2020;13:1. PMID 32116540
08: Batten FE. Three cases of myopathy, infantile type. Brain 1903;27:147-8.
09: Bouman K, Groothuis JT, Doorduin J, et al. LAMA2-related muscular dystrophy across the life span: a cross-sectional study. Neurol Genet 2023;9(5):e200089. PMID 37476021
10: Bushby K, Anderson LV, Pollitt C, Naom I, Muntoni F, Bindoff L. Abnormal merosin in adults. A new form of late onset muscular dystrophy not linked to chromosome 6q2. Brain 1998;121:581-8. PMID 9577386
11: Carboni N, Marrosu G, Porcu M, et al. Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin-α2-chain gene: a chance association or a novel phenotype? Muscle Nerve 2011;44(5):826-8. PMID 22006699
12: Carmignac V, QuÈrÈ R, Durbeej M.: Proteasome inhibition improves the muscle of laminin-alpha 2 chain-deficient mice. Hum Mol Genet 2011;20(3):541-52. PMID 21084425
13: Chun SJ, Rasband MN, Sidman RL, Habib AA, Vartanian T. Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination. J Cell Biol 2003;163(2):397-408. PMID 14581460
14: Clement EM, Feng L, Mein R, et al. Relative frequency of congenital muscular dystrophy subtypes: analysis of the UK diagnostic service 2001-2008. Neuromuscul Disord 2012;22(6):522-7. PMID 22480491
15: Cornwall KM, Butterfield RJ, Hernandez A, Heatwole C, Johnson NE. A qualitative approach to health related quality-of-life in congenital muscular dystrophy. J Neuromuscul Dis 2018;5(2):251-5. PMID 29689733
16: Di Blasi C, Piga D, Brioschi P, et al. LAMA2 gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect. Arch Neurol 2005;62(10):1582-6. PMID 16216942
17: Doe JA, Wuebbles RD, Allred ET, Rooney JE, Elorza M, Burkin DJ. Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A. J Cell Sci 2011;124(Pt 13):2287-97. PMID 21652631
18: Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, Miller JB. Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 2005;14(8):1029-40. PMID 15757977
19: Dowling JJ, Gonorazky HD, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet A 2018;176(4):804-41. PMID 28889642
20: Dubowitz DJ, Tyszka JM, Sewry CA, Moats RA, Scadeng M, Dubowitz V. High resolution magnetic resonance imaging of the brain in the dy/dy mouse with merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 2000;10(4-5):292-8. PMID 10838257
21: Echenne B, Rivier F, Jellali AJ, Azais M, Mornet D, Pons F. Merosin positive congenital muscular dystrophy with mental deficiency, epilepsy and MRI changes in the cerebral white matter. Neuromuscul Disord 1997;7:187-90. PMID 9185183
22: Elbaz M, Yanay N, Aga-Mizrachi S, et al. Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. Ann Neurol 2012;71(5):699-708. PMID 22522482
23: Erb M, Meinen S, Barzaghi P, et al. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther 2009;331(3):787-95. PMID 19759319
24: Fadiloglu E, Ozten G, Unal C, Talim B, Topaloglu H, Beksac MS. Prenatal diagnosis of merosin-deficient muscular dystrophy. Fetal Pediatr Pathol 2018;37(6):418-23. PMID 30358464
25: Fontes-Oliveira CC, M Soares Oliveira B, Körner Z, M Harandi V, Durbeej M. Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study. Sci Rep 2018;8(1):16302. PMID 30389963
26: Gawlik KI, Akerlund M, Carmignac V, Elamaa H, Durbeej M.: Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency. PLoS One 2010;5(7):e11549. PMID 20657839
27: Gawlik KI, Durbeej M. A family of laminin α2 chain-deficient mouse mutants: advancing the research on LAMA2-CMD. Front Mol Neurosci 2020;13:59. PMID 32457577
28: Gawlik KI, Li JY, Petersén A, Durbeej M. Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy. Hum Mol Genet 2006;15(18):2690-700. PMID 16893907
29: Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, Abbs S, Brueton L, Childs AM, Jungbluth H, De Goede CG, Lynch B, Lin JP, Chow G, Sousa C, O'Mahony O, Majumdar A, Straub V, Bushby K, Muntoni F.: Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord 2010;20(4):241-50. PMID 20207543
30: Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann Neurol 2009;65(1):47-56. PMID 19086074
31: Girgenrath M, Dominov JA, Kostek CA, Miller JB. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest 2004;114(11):1635-9. PMID 15578095
32: Graziano A, Bianco F, D'Amico A, et al. Prevalence of congenital muscular dystrophy in Italy: a population study. Neurology 2015;84(9):904-11.** PMID 25653289
33: Grewal PK, Hewitt JE. Glycosylation defects: a new mechanism for muscular dystrophy. Hum Mol Genet 2003;12 Spec No 2:R259-64. PMID 12925572
34: Guicheney P, Vignier N, Zhang X, et al. PCR based mutation screening of the laminin alpha2 chain gene (LAMA2): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy. J Med Genet 1998;35(3):211-7. PMID 9541105
35: Hara Y, Mizobe Y, Miyatake S, et al. Exon skipping using antisense oligonucleotides for laminin-alpha2-deficient muscular dystrophy. Methods Mol Biol 2018;1828:553-64. PMID 30171567
36: Harris E, McEntagart M, Topf A, et al. Clinical and neuroimaging findings in two brothers with limb girdle muscular dystrophy due to LAMA2 mutations. Neuromuscul Disord 2017;27(2):170-4. PMID 27932089
37: Hayashi YK, Engvall E, Arikawa-Hirasawa K, et al. Abnormal localization of laminin subunits in muscular dystrophies. J Neurol Sci 1993;119(1):53-64. PMID 8246011
38: Hayashi YK, Tezak Z, Momoi T, et al. Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 2001;11(4):350-9. PMID 11369186
39: He Y, Jones KJ, Vignier N, et al. Congenital muscular dystrophy with primary partial laminin alpha2 chain deficiency: molecular study. Neurology 2001;57(7):1319-22. PMID 11591858
40: Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nature Gen 1995;11:216-8. PMID 7550355
41: Hillaire D, Leclerc A, Faure S, et al. Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Hum Mol Genet 1994;3(9):1657-61. PMID 7833925
42: Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F. Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 2005;62(7-8):809-23. PMID 15868406
43: Jones KJ, Morgan G, Johnston H, et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet 2001;38(10):649-57. PMID 11584042
44: Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2015;84(13):1369-78. PMID 25825463
45: Kemaladewi DU, Bassi PS, Erwood S, et al. A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene. Nature 2019;572(7767):125-30. PMID 31341277
46: Kemaladewi DU, Maino E, Hyatt E, et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med 2017;23(8):984-9. PMID 28714989
47: Kolbel H, Hathazi D, Jennings M, Horvath R, Roos A, Schara U. Identification of candidate protein markers in skeletal muscle of laminin-211-deficient CMD type 1A-patients. Front Neurol 2019;10:470. PMID 31133972
48: Kuang W, Xu H, Vilquin JT, Engvall E. Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest 1999;79:1601-13. PMID 10616210
49: Lacramioara F, Dowling JJ. Zebrafish models of LAMA2-related congenital muscular dystrophy (MDC1A). Front Mol Neurosci 2020;13:122. PMID 32742259
50: Leite CC, Reed UC, Otaduy MC, et al. Congenital muscular dystrophy with merosin deficiency: 1H MR spectroscopy and diffusion-weighted MR imaging. Radiology 2005;235(1):190-6. PMID 15703311
51: Li ZF, Shelton GD, Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol 2005;166(2):491-7. PMID 15681832
52: Marques J, Duarte ST, Costa S, et al. Atypical phenotype in two patients with LAMA2 mutations. Neuromuscul Disord 2014;24(5):419-24. PMID 24534542
53: McKee KK, Yurchenco PD. Amelioration of muscle and nerve pathology of Lama2-related dystrophy by AAV9-laminin-αLN linker protein. JCI Insight 2022;7(13):e158397. PMID 35639486
54: Meinen S, Lin S, Thurnherr R, Erb M, Meier T, Rüegg MA.: Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. EMBO Mol Med 2011;3(8):465-79. PMID 21674808
55: Mendell JR, Sahenk Z, Prior T. The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability. J Child Neurol 1995;10:150-9. PMID 7782608
56: Mercuri E, Muntoni F, Berardinelli A, et al. Somatosensory and visual evoked potentials in congenital muscular dystrophy: correlation with MRI changes and muscle merosin status. Neuropediatrics 1995;26(1):3-7. PMID 7791947
57: Mercuri E, Rutherford M, De Vile C, et al. Early white matter changes on brain magnetic resonance imaging in a newborn affected by merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 2001;11(3):297-9. PMID 11297945
58: Mitrpant C, Fletcher S, Iversen PL, Wilton SD. By-passing the nonsense mutation in the 4(CV) mouse model of muscular dystrophy by induced exon skipping. J Gene Med 2009;11(1):46-56. PMID 19006096
59: Miyagoe-Suzuki Y, Nakagawa M, Takeda S. Merosin and congenital muscular dystrophy. Microscopy Res Tech 2000;48:181-91. PMID 10679965
60: Moghadaszadeh B, Petit N, Jaillard C, et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet 2001;29(1):17-8. PMID 11528383
61: Moll J, Barzaghi P, Lin S, et al. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 2001;413(6853):302-7. PMID 11565031
62: Moreira Soares Oliveira B, Gawlik KI, Durbeej M, Holmberg J. Exploratory profiling of urine MicroRNAs in the dy2J/dy2J mouse model of LAMA2-CMD: relation to disease progression. PLoS Curr 2018;10. PMID 30430039
63: Muntoni F, Valero de Bernabe B, Bittner R, et al. 114th ENMC International Workshop on Congenital Muscular Dystrophy (CMD) 17-19 January 2003, Naarden, The Netherlands: (8th Workshop of the International Consortium on CMD; 3rd Workshop of the MYO-CLUSTER project GENRE). Neuromuscul Disord 2003;13(7-8):579-88. PMID 12921796
64: Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 2004;14(10):635-49. PMID 15351421
65: Nakagawa M, Miyagoe-Suzuki Y, Ikezoe K, et al. Schwann cell myelination occurred without basal lamina formation in laminin alpha2 chain-null mutant (dy3K/dy3K) mice. Glia 2001;35(2):101-10. PMID 11460266
66: Natera-de Benito D, Muchart J, Itzep D, et al. Epilepsy in LAMA2-related muscular dystrophy: An electro-clinico-radiological characterization. Epilepsia 2020;61(5):971-83. PMID 32266982
67: Nelson I, Stojkovic T, Allamand V, et al. Laminin α2 deficiency-related muscular dystrophy mimicking Emery-Dreifuss and collagen VI related diseases. J Neuromuscul Dis 2015;2(3):229-40. PMID 27858741
68: Nguyen Q, Lim KRQ, Yokota T. Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy. Appl Clin Genet 2019;12:113-30. PMID 31308722
69: North K, Beggs AH. Deficiency of a skeletal muscle isoform of alpha-actinin (alpha-actinin-3) in merosin-positive congenital muscular dystrophy. Neuromuscul Disord 1996;6(4):229-35. PMID 8887951
70: O'Grady GL, Lek M, Lamande SR, et al. Diagnosis and etiology of congenital muscular dystrophy: we are halfway there. Ann Neurol 2016;80(1):101-11. PMID 27159402
71: Oliveira J, Gruber A, Cardoso M, et al. LAMA2 gene mutation update: toward a more comprehensive picture of the laminin-alpha2 variome and its related phenotypes. Hum Mutat 2018;39(10):1314-37. PMID 30055037
72: Oliveira J, Santos R, Soares-Silva I, et al. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. Clin Genet 2008;74(6):502-12. PMID 18700894
73: Packer D, Martin PT. Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dyW mouse model of MDC1A. Mol Ther Methods Clin Dev 2021;21:274-87. PMID 33869655
74: Patton BL, Wang B, Tarumi YS, Seburn KL, Burgess RW. A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination. J Cell Sci 2008;121(Pt 10):1593-604. PMID 18430779
75: Peat RA, Smith JM, Compton AG, et al. Diagnosis and etiology of congenital muscular dystrophy. Neurology 2008;71(5):312-21. PMID 18160674
76: Pegoraro E, Mancias P, Swerdlow SH, et al. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol 1996;40:782-91. PMID 8957020
77: Pegoraro E, Marks H, Garcia CA, et al. Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology 1998;51(1):101-10. PMID 9674786
78: Philpot J, Cowan F, Pennock J, et al. Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging. Neuromuscul Disord 1999;9:81-5. PMID 10220862
79: Prandini P, Berardinelli A, Fanin M, et al. LAMA2 loss-of-function mutation in a girl with a mild congenital muscular dystrophy. Neurology 2004;63(6):1118-21. PMID 15452315
80: Previtali SC, Zambon AA. LAMA2 neuropathies: human findings and pathomechanisms from mouse models. Front Mol Neurosci 2020;13:60. PMID 32390798
81: Qiao C, Dai Y, Nikolova VD, et al. Amelioration of muscle and nerve pathology in LAMA2 muscular dystrophy by AAV9-mini-agrin. Mol Ther Methods Clin Dev 2018;9:47-56. PMID 29766020
82: Reinhard JR, Lin S, McKee KK, et al. Linker proteins restore basement membrane and correct LAMA2‐related muscular dystrophy in mice. Sci Transl Med 2017;9(396):eaal4649. PMID 28659438
83: Rooney JE, Knapp JR, Hodges BL, Wuebbles RD, Burkin DJ. Laminin‐111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin‐deficient congenital muscular dystrophy. Am J Pathol 2012;180(4):1593-602. PMID 22322301
84: Sarkozy A, Foley AR, Zambon AA, Bönnemann CG, Muntoni F. LAMA2-related dystrophies: clinical phenotypes, disease biomarkers, and clinical trial readiness. Front Mol Neurosci 2020;13:123.** PMID 32848593
85: Sellick GS, Longman C, Brockington M, et al. Localisation of merosin-positive congenital muscular dystrophy to chromosome 4p16.3. Hum Genet 2005;117(2-3):207-12. PMID 15886997
86: Sewry C, Philpot J, Sorokin LM, et al. Diagnosis of merosin (laminin-2) deficient congenital muscular dystrophy by skin biopsy. Lancet 1996;347:582-4. PMID 8596321
87: Sframeli M, Sarkozy A, Bertoli M, et al. Congenital muscular dystrophies in the UK population: clinical and molecular spectrum of a large cohort diagnosed over a 12-year period. Neuromuscul Disord 2017;27(9):793-803. PMID 28688748
88: Shibuya S, Wakayama Y, Inoue M, Kojima H, Oniki H. Merosin (laminin-2) localization in basal lamina of normal skeletal muscle fibers and changes in plasma membrane of merosin-deficient skeletal muscle fibers. Med Electron Microsc 2003;36(4):213-20. PMID 16228654
89: Shukry M, Guruli ZV, Ramadhyani U. Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent. Paediatr Anaesth 2006;16(4):462-5. PMID 16618304
90: Spyrou N, Philpot J, Foale R, Camici PG, Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. Am Heart J 1998;136(3):474-6. PMID 9736139
91: Sunada Y, Edgar TS, Lotz BP, Rust RS, Campbell KP. Merosin-negative congenital muscular dystrophy associated with extensive brain abnormalities. Neurology 1995;45:2084-9. PMID 7501163
92: Tan D, Ge L, Fan Y, et al. Muscle magnetic resonance imaging in patients with LAMA2-related muscular dystrophy. Neuromuscul Disord 2021;31(11):1144-53. PMID 34702656
93: Tan E, Topaloglu H, Sewry C, et al. Late onset muscular dystrophy with cerebral white matter changes due to partial merosin deficiency. Neuromuscul Disord 1997;7:85-9. PMID 9131648
94: Taratuto AL, Lubieniecki F, Diaz D, et al. Merosin-deficient congenital muscular dystrophy associated with abnormal cerebral cortical gyration: an autopsy study. Neuromuscul Disord 1999;9:86-94. PMID 10220863
95: Tezak Z, Prandini P, Boscaro M, et al. Clinical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (LAMA2) deficiency. Hum Mutat 2003;21(2):103-11. PMID 12552556
96: Tome FM, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III 1994;317(4):351-7. PMID 8000914
97: Tsao CY, Mendell JR. The childhood muscular dystrophies: making order out of chaos. Semin Neurol 1999;19(1):9-23. PMID 10711985
98: Tubridy N, Fontaine B, Eymard B. Congenital myopathies and congenital muscular dystrophies. Curr Opin Neurol 2001;14(5):575-82. PMID 11562568
99: Vachon PH, Loechel F, Xu H, Wewer UM, Engvall E. Merosin and laminin in myogenesis: specific requirement for merosin in myotube stability and survival. J Cell Biol 1996;134:1483-97. PMID 8830776
100: Vainzof M, Richard P, Herrmann R, et al. Prenatal diagnosis in laminin alpha2 chain (merosin)-deficient congenital muscular dystrophy: a collective experience of five international centers. Neuromuscul Disord 2005;15(9-10):588-94. PMID 16084089
101: Van Ry PM, Minogue P, Hodges BL, Burkin DJ. Laminin-111 improves muscle repair in a mouse model of merosin deficient congenital muscular dystrophy. Hum Mol Genet 2014;23(2):383-96. PMID 24009313
102: Verma S, Goyal P, Guglani L, Peinhardt C, Pelzek D, Barkhaus PE. COL6A and LAMA2 mutation congenital muscular dystrophy: a clinical and electrophysiological study. J Clin Neuromuscul Dis 2018 Mar;19(3):108-16. PMID 29465610
103: Vigliano P, Dassi P, Blasi CD, Mora M, Jarre L. LAMA2 stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. Eur J Paediatr Neurol 2009;13(1):72-6. PMID 18406646
104: Villanova M, Malandrini A, Sabatelli P, et al. Localization of laminin alpha 2 chain in normal human central nervous system: an immunofluorescence and ultrastructural study. Acta Neuropathol (Berl) 1997;94(6):567-71. PMID 9444358
105: Voit T, Sewry CA, Meyer K, et al. Preserved merosin M-chain (or laminin-alpha 2) expression in skeletal muscle distinguishes Walker-Warburg syndrome from Fukuyama muscular dystrophy and merosin-deficient congenital muscular dystrophy. Neuropediatrics 1995;26(3):148-55. PMID 7477753
106: Wang CH, Bonnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol 2010;25(12):1559-81. PMID 21078917
107: Xiong H, Tan D, Wang S, Song S, et al. Genotype/phenotype analysis in Chinese laminin-α2 deficient congenital muscular dystrophy patients. Clin Genet 2015;87(3):233-43. PMID 24611677
108: Xu H, Wu XR, Wewer UM, Engvall E. Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet 1994;8(3):297-302. PMID 7874173
109: Xu L, Lu PJ, Wang CH, et al. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of alpha-dystroglycan and improves muscle functions. Mol Ther 2013;21(10):1832-40. PMID 23817215
110: Yamada H, Shimizu T, Tanaka T, Campbell KP, Matsumura K. Dystroglycan is a binding protein of laminin and merosin in peripheral nerve. FEBS Lett 1994;352(1):49-53. PMID 7925941
111: Yanay N, Rabie M, Nevo Y. Impaired regeneration in dystrophic muscle-new target for therapy. Front Mol Neurosci 2020;13:69. PMID 32523512
112: Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001;1(5):717-24. PMID 11709191
113: Yu Q, Sali A, Van der Meulen J, et al. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One 2013;8(6):e65468. PMID 23762378
114: Yurchenco PD, McKee KK. Linker protein repair of LAMA2 dystrophic neuromuscular basement membranes. Front Mol Neurosci 2019;12:305. PMID 31920536
115: Yurchenco PD, O'Rear JJ. Basal lamina assembly. Curr Opin Cell Biol 1994;6:674-81. PMID 7833047
116: Zhang X, Voulteenaho R, Tryggvason K. Structure of the human laminin alpha 2-chain gene (LAMA2), which is affected in congenital muscular dystrophy. J Biol Chem 1996;271:27661-9. PMID 8910357

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Neil Datta MD

Dr. Datta of Harvard Medical School has no relevant financial relationships to disclose.
See Profile
Partha Ghosh MD

Dr. Ghosh of Boston Children's Hospital and Harvard Medical School received honorariums from Sarepta and Pfizer as an ad hoc advisory board member and/or speaker and an honorarium from CVS Caremark as a consultant.
See Profile

Editor

Aravindhan Veerapandiyan MD

Dr. Veerapandiyan of University of Arkansas for Medical Sciences has no relevant financial relationships to disclose.
See Profile

Former Authors

Christine J DiDonato PhD
Amber Buehner APRN NP
Vamshi K Rao MBBS MD
Gyula Acsadi MD PhD (original author), and James Wymer MD PhD

Patient Profile

Age range of presentation: 0 to 23 months
Sex preponderance: female>male, >1:1
Heredity: heredity typical

heredity may be a factor

autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Congenital hereditary muscular dystrophy: 359.0
ICD-10: Congenital muscular dystrophy: G71.2
OMIM: Muscular dystrophy, congenital merosin-deficient: #607855

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Congenital muscular dystrophy: merosin deficient form

Associated Disorders

Fukuyama muscular dystrophy
Muscle-eye-brain disease
Walker-Warburg disease

Differential Diagnosis

other forms of congenital myopathies
structural defects of muscle or metabolic myopathies
elevated creatine kinase
muscle histology
floppy infant syndrome
- lack of encephalopathy
- normal cranial nerve
- decreased or absent deep tendon reflexes
- decreased muscle bulk
- central hypotonia
- spinal muscular atrophy (type I)
- congenital myasthenia
- rigid spine syndrome
- Fukuyama muscular dystrophy
- Walker-Warburg disease
- glycosyltransferase deficiency
- “eye-muscle-brain disease”
- white matter abnormalities

Also Relevant

Becker muscular dystrophy
Childhood ataxia with central nervous system hypomyelination
Congenital muscular dystrophies
Duchenne muscular dystrophy
Emery-Dreifuss muscular dystrophy
- Gene therapy of muscular dystrophy
- Ullrich congenital muscular dystrophy
- Walker-Warburg syndrome

Clinical Categories

Patient Handouts

Muscular dystrophy

Web References

Clinical Trials

NIH: Congenital Muscular Dystrophy

Congenital muscular dystrophy: merosin deficient form …

Congenital muscular dystrophy: merosin deficient form

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Neurogenetics and genetic and genomic testing

Cerebro-oculo-facio-skeletal syndrome

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Schizencephaly

Fetal anticonvulsant syndrome

Congenital muscular dystrophy: merosin deficient form

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Neurogenetics and genetic and genomic testing

Cerebro-oculo-facio-skeletal syndrome

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Schizencephaly

Fetal anticonvulsant syndrome

This is an article preview.
Start a Free Account
to access the full version.